HK1119578A1 - Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease - Google Patents

Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Info

Publication number
HK1119578A1
HK1119578A1 HK08111743.9A HK08111743A HK1119578A1 HK 1119578 A1 HK1119578 A1 HK 1119578A1 HK 08111743 A HK08111743 A HK 08111743A HK 1119578 A1 HK1119578 A1 HK 1119578A1
Authority
HK
Hong Kong
Prior art keywords
inflammatory disease
antagonists
ocular inflammatory
treat autoimmune
autoimmune ocular
Prior art date
Application number
HK08111743.9A
Other languages
English (en)
Inventor
Daniel J Cua
Robert A Kastelein
Van T Tsai
Rachel Caspi
Phyllis Silver
Dror Luger
Original Assignee
Schering Corp
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1119578(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp, Us Gov Health & Human Serv filed Critical Schering Corp
Publication of HK1119578A1 publication Critical patent/HK1119578A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
HK08111743.9A 2005-09-01 2008-10-24 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease HK1119578A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71379205P 2005-09-01 2005-09-01
US83731206P 2006-08-11 2006-08-11
PCT/US2006/033840 WO2007027761A2 (en) 2005-09-01 2006-08-30 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Publications (1)

Publication Number Publication Date
HK1119578A1 true HK1119578A1 (en) 2009-03-13

Family

ID=37686002

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08111743.9A HK1119578A1 (en) 2005-09-01 2008-10-24 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Country Status (22)

Country Link
US (6) US20080199460A1 (de)
EP (3) EP2322219A3 (de)
JP (3) JP2009507023A (de)
CN (1) CN101296706B (de)
AT (1) ATE445415T1 (de)
AU (1) AU2006284841B2 (de)
BR (1) BRPI0615297A2 (de)
CA (1) CA2621086A1 (de)
CY (1) CY1110606T1 (de)
DE (1) DE602006009834D1 (de)
DK (1) DK1933869T3 (de)
ES (1) ES2333260T3 (de)
HK (1) HK1119578A1 (de)
HR (1) HRP20100014T1 (de)
NO (1) NO20081574L (de)
NZ (2) NZ566424A (de)
PL (1) PL1933869T3 (de)
PT (1) PT1933869E (de)
RS (1) RS51142B (de)
SI (1) SI1933869T1 (de)
TW (2) TWI463993B (de)
WO (1) WO2007027761A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
KR101453570B1 (ko) * 2005-12-02 2014-10-22 제넨테크, 인크. Ｉｌ-22 및 ｉｌ-22ｒ에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JP5337055B2 (ja) * 2007-02-28 2013-11-06 メルク・シャープ・アンド・ドーム・コーポレーション 免疫性障害の処置のための組合せ治療
ES2465223T3 (es) * 2007-04-27 2014-06-05 Zymogenetics, Inc. Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
EP2174667B1 (de) * 2007-07-26 2017-01-04 Osaka University Mittel zur behandlung von augenentzündungen mit interleukin-6-rezeptorhemmer als wirkstoff
WO2009023267A2 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Methods for modulating development and expansion of il-17 expressing cells
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
JP5886523B2 (ja) * 2008-01-09 2016-03-16 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼の炎症性障害を処置するための治療組成物
CN104151428B (zh) 2008-02-21 2017-07-14 麒麟-安姆根有限公司 Il‑17ra‑il‑17rb拮抗物及其用途
KR20150002874A (ko) 2008-05-05 2015-01-07 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
US10117906B2 (en) 2009-01-09 2018-11-06 The Schepens Eye Research Institute, Inc. Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
KR101766927B1 (ko) * 2009-04-01 2017-08-09 제넨테크, 인크. 인슐린 저항성 장애의 치료
EP2427203B1 (de) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f-antikörper und deren verwendung
US9301997B2 (en) 2009-09-21 2016-04-05 Peptinov Sas Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides
LT2523688T (lt) 2010-01-15 2018-03-12 Kirin-Amgen, Inc. Antikūno kompozicija ir terapiniai režimai
US20110311527A1 (en) * 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
HUE041590T2 (hu) 2010-07-29 2019-05-28 Eleven Biotherapeutics Inc Kiméra IL-1 receptor I agonisták és antagonisták
WO2012045848A1 (en) * 2010-10-08 2012-04-12 Novartis Ag Methods of treating psoriasis using il-17 antagonists
EP3456740A1 (de) 2010-11-04 2019-03-20 Boehringer Ingelheim International GmbH Anti-il-23-antikörper
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EP2768946A1 (de) * 2011-10-21 2014-08-27 Baylor College Of Medicine Verfahren zur messung von entzündungen der bindehaut von patienten mit tränenfilmdysfunktion
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
US11078265B2 (en) 2012-05-03 2021-08-03 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
LT2852615T (lt) 2012-05-22 2019-02-11 Bristol-Myers Squibb Company Il-17a/f il-23 bispecifiniai antikūnai ir jų panaudojimai
EP2931311A4 (de) * 2012-12-13 2016-08-17 Merck Sharp & Dohme Lyophilisierte kugelförmige pellets von anti-il-23-antikörpern
WO2014107737A2 (en) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
EP2968468B1 (de) 2013-03-13 2021-07-14 Buzzard Pharmaceuticals AB Chimäre zytokine formulierungen zur okularen verabreichung
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
EA039598B9 (ru) 2014-09-03 2022-03-10 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23а и фно-альфа, и его применение
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
KR20220151045A (ko) 2014-12-23 2022-11-11 4디 파마 리서치 리미티드 면역 조정
HUE037476T2 (hu) 2014-12-23 2018-08-28 4D Pharma Res Ltd Pirin polipeptid és immunmodulálás
EP3242714B1 (de) 2014-12-31 2021-06-02 Stimwave Technologies Incorporated Antennenanordnung
WO2016123329A2 (en) * 2015-01-28 2016-08-04 Genentech, Inc. Gene expression markers and treatment of multiple sclerosis
CN104725514A (zh) * 2015-02-06 2015-06-24 中国药科大学 新型il23拮抗剂
EA201890050A1 (ru) 2015-06-15 2018-06-29 4Д Фарма Рисёрч Лимитед Композиции, содержащие бактериальные штаммы
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ME03511B (de) 2015-06-15 2020-04-20 4D Pharma Res Ltd Zusammensetzungen mit bakterienstämmen
EA201890048A1 (ru) 2015-06-15 2018-06-29 4Д Фарма Рисёрч Лимитед Композиции, содержащие бактериальные штаммы
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
BR112018005175A2 (pt) 2015-09-17 2018-10-16 Amgen Inc predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23
EP3209310B1 (de) 2015-11-20 2018-01-31 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
LT3313423T (lt) 2016-03-04 2019-06-25 4D Pharma Plc Kompozicijos, apimančios bakterinius blautia kamienus, skirtos visceralinio hiperjautrumo gydymui
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
RS61872B1 (sr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
EP3630942B1 (de) 2017-05-24 2022-11-30 4D Pharma Research Limited Zusammensetzungen mit bakterienstamm
AU2018285453B2 (en) 2017-06-14 2020-03-19 Cj Bioscience, Inc. Compositions comprising a bacterial strain of the genus Megasphaera and uses thereof
EP3638271B1 (de) 2017-06-14 2020-10-14 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
MX2023001491A (es) * 2020-08-05 2023-03-08 Synthekine Inc Moleculas de union a gp130 y metodos de uso.
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0617706B1 (de) 1991-11-25 2001-10-17 Enzon, Inc. Multivalente antigen-bindende proteine
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
NZ306653A (en) 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
AU7296801A (en) 2000-06-22 2002-02-05 Amgen Inc Il-17 molecules and uses thereof
WO2002097048A2 (en) 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
CA2501786C (en) * 2002-10-30 2015-02-17 Genentech, Inc. Inhibition of il-17 production
WO2004071517A2 (en) * 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
TWI357336B (en) 2003-03-10 2012-02-01 Schering Corp Uses of il-23 agonists and antagonists; related re
AU2004239288B2 (en) * 2003-05-09 2010-01-28 Centocor, Inc. IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
KR100945327B1 (ko) 2003-07-08 2010-03-08 제넨테크, 인크. Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
AU2005241020B2 (en) * 2004-05-03 2008-07-10 Merck Sharp & Dohme Corp. Use of IL-17 expression to predict skin inflammation; methods of treatment
ATE476993T1 (de) 2004-06-07 2010-08-15 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
WO2006007486A2 (en) * 2004-07-01 2006-01-19 New York University COMPOSITIONS AND METHODS FOR MODULATION OF RORϜt
DE102005032499B4 (de) * 2004-07-13 2009-10-22 Lg Electronics Inc. Dämpfer zur Vibrationsdämpfung und damit ausgerüstete Waschmaschine
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
JP2008520712A (ja) * 2004-11-19 2008-06-19 シンタ ファーマシューティカルズ コーポレーション ピリミジン化合物及びその使用
WO2006057859A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
TWI363091B (en) * 2004-12-20 2012-05-01 Schering Corp Uses of mammalian cytokine; related reagents
AR051805A1 (es) 2004-12-21 2007-02-07 Centocor Inc Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos
EP1848743A2 (de) 2005-02-14 2007-10-31 Wyeth Interleukin-17f antikörper und andere antagonisten der il-17f signalübertragung sowie deren verwendungen
HUE042561T2 (hu) * 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
CN101379085B (zh) 2005-06-30 2013-03-27 Abbvie公司 Il-12/p40结合蛋白
EP3190125A1 (de) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Mittels engineering hergestellte anti-il-23r-antikörper
DK3219328T3 (da) 2005-12-29 2020-07-13 Janssen Biotech Inc Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds

Also Published As

Publication number Publication date
ATE445415T1 (de) 2009-10-15
EP2116258A1 (de) 2009-11-11
JP2011184466A (ja) 2011-09-22
SI1933869T1 (sl) 2010-02-26
PL1933869T3 (pl) 2010-06-30
BRPI0615297A2 (pt) 2011-05-17
EP1933869A2 (de) 2008-06-25
PT1933869E (pt) 2009-12-24
US20130323251A1 (en) 2013-12-05
ES2333260T3 (es) 2010-02-18
DK1933869T3 (da) 2010-03-01
WO2007027761A3 (en) 2007-05-03
NZ566424A (en) 2011-10-28
TW201235050A (en) 2012-09-01
US20100111950A1 (en) 2010-05-06
TWI463993B (zh) 2014-12-11
US8524230B2 (en) 2013-09-03
JP5462838B2 (ja) 2014-04-02
US20100111954A1 (en) 2010-05-06
TWI372061B (en) 2012-09-11
US20080199460A1 (en) 2008-08-21
CN101296706A (zh) 2008-10-29
DE602006009834D1 (de) 2009-11-26
EP2322219A3 (de) 2013-06-05
AU2006284841B2 (en) 2012-11-08
CY1110606T1 (el) 2015-04-29
JP2014005285A (ja) 2014-01-16
JP2009507023A (ja) 2009-02-19
CA2621086A1 (en) 2007-03-08
EP2322219A2 (de) 2011-05-18
NZ595262A (en) 2013-03-28
CN101296706B (zh) 2011-11-30
WO2007027761A2 (en) 2007-03-08
US20110142831A1 (en) 2011-06-16
AU2006284841A1 (en) 2007-03-08
EP1933869B1 (de) 2009-10-14
US20140248279A1 (en) 2014-09-04
TW200800259A (en) 2008-01-01
NO20081574L (no) 2008-05-30
HRP20100014T1 (hr) 2010-02-28
RS51142B (sr) 2010-10-31

Similar Documents

Publication Publication Date Title
TWI372061B (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
WO2007022506A3 (en) Methods and compositions for treating neurological disease
WO2010144721A3 (en) Model systems and treatment regimes for treatment of neurological disease
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2007098089A3 (en) Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs
IN2012DN02471A (de)
UA96926C2 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2010101301A9 (en) Prophylaxis and treatment of macular degeneration and retinopathy using a prdx protein
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
EA200970293A1 (ru) Новые производные 5-тиоксилопиранозы
UA97289C2 (ru) Соединения и их композиция как модуляторы gpr119 активности

Legal Events

Date Code Title Description
REV Revocation after opposition